Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has been given a consensus recommendation of “Hold” by the sixteen ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $22.09.
Several equities analysts recently issued reports on the company. Credit Suisse Group set a $17.00 price target on Alder Biopharmaceuticals and gave the company a “hold” rating in a report on Tuesday. Wells Fargo & Co assumed coverage on Alder Biopharmaceuticals in a report on Tuesday. They issued an “outperform” rating on the stock. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a “buy” rating in a report on Monday. Cantor Fitzgerald set a $21.00 price target on Alder Biopharmaceuticals and gave the company a “hold” rating in a report on Tuesday. Finally, BidaskClub upgraded Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday.
In other Alder Biopharmaceuticals news, insider John A. Latham sold 25,002 shares of the firm’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $13.42, for a total transaction of $335,526.84. Following the transaction, the insider now owns 250,514 shares in the company, valued at $3,361,897.88. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey T. L. Smith sold 5,040 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $18.00, for a total value of $90,720.00. Following the transaction, the director now owns 5,871 shares in the company, valued at approximately $105,678. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,120 shares of company stock worth $1,407,922. 17.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Cornerstone Wealth Management LLC bought a new position in Alder Biopharmaceuticals during the third quarter worth about $400,000. SG Americas Securities LLC bought a new position in Alder Biopharmaceuticals during the second quarter worth about $107,000. Tower Research Capital LLC TRC bought a new position in Alder Biopharmaceuticals during the second quarter worth about $128,000. Xact Kapitalforvaltning AB bought a new position in Alder Biopharmaceuticals during the first quarter worth about $142,000. Finally, LPL Financial LLC bought a new position in Alder Biopharmaceuticals during the first quarter worth about $156,000.
Shares of NASDAQ:ALDR traded down $0.07 during midday trading on Thursday, reaching $14.18. The company’s stock had a trading volume of 256,553 shares, compared to its average volume of 795,414. Alder Biopharmaceuticals has a fifty-two week low of $9.55 and a fifty-two week high of $20.87. The firm has a market cap of $979.19 million, a PE ratio of -2.86 and a beta of 2.70. The company has a debt-to-equity ratio of 0.73, a quick ratio of 10.88 and a current ratio of 10.88.
Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.13) by $0.22. On average, analysts anticipate that Alder Biopharmaceuticals will post -4.73 EPS for the current fiscal year.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.
Read More: How analysts view the yield curve
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.